We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed at $79.76 in the latest trading session, marking a +1.49% move from the prior day. This change outpaced the S&P 500's 1.39% loss on the day. On the other hand, the Dow registered a gain of 0.6%, and the technology-centric Nasdaq decreased by 2.77%.
The pharmaceutical's shares have seen an increase of 0.22% over the last month, not keeping up with the Medical sector's gain of 1.98% and the S&P 500's gain of 4.43%.
Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on July 25, 2024. The company is predicted to post an EPS of $0.96, indicating a 11.11% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $12.57 billion, up 10.14% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.05 per share and a revenue of $51.95 billion, signifying shifts of +11.57% and +13.41%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.33% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 19.41. This indicates a premium in contrast to its industry's Forward P/E of 14.98.
It is also worth noting that AZN currently has a PEG ratio of 1.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.88.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 163, this industry ranks in the bottom 36% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AZN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Astrazeneca (AZN - Free Report) closed at $79.76 in the latest trading session, marking a +1.49% move from the prior day. This change outpaced the S&P 500's 1.39% loss on the day. On the other hand, the Dow registered a gain of 0.6%, and the technology-centric Nasdaq decreased by 2.77%.
The pharmaceutical's shares have seen an increase of 0.22% over the last month, not keeping up with the Medical sector's gain of 1.98% and the S&P 500's gain of 4.43%.
Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on July 25, 2024. The company is predicted to post an EPS of $0.96, indicating a 11.11% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $12.57 billion, up 10.14% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.05 per share and a revenue of $51.95 billion, signifying shifts of +11.57% and +13.41%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.33% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 19.41. This indicates a premium in contrast to its industry's Forward P/E of 14.98.
It is also worth noting that AZN currently has a PEG ratio of 1.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.88.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 163, this industry ranks in the bottom 36% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AZN in the coming trading sessions, be sure to utilize Zacks.com.